2901 South Loop Drive
206 articles with NewLink Genetics
NewLink Genetics Presents Encouraging Updated Phase 1 Data with Indoximod Plus Chemotherapy in Frontline AML in an Oral Session at 2018 ASH Annual Meeting
Updated Phase 1 data for indoximod plus standard-of-care chemotherapy in newly diagnosed AML show post-induction minimal residual disease (MRD) negativity rate of 86% and post-consolidation MRD negativity of 100%
11/12/2018As an outbreak of the Ebola virus in the Democratic Republic of the Congo worsens, a team of health officials has taken four experimental vaccines to the front lines and begun to administer it to patients who may have been exposed to the deadly virus.
NewLink Genetics Announces Indoximod Biomarker Data and Prodrug NLG802 Pharmacokinetic Data to be Presented at SITC 2018
NewLink Genetics Corporation announced today that two abstracts were accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting being held November 7-11, 2018 in Washington, D.C.
NewLink Genetics has announced, with the company restructuring and layoffs, they are refocusing on indoximod.
NewLink Genetics Announces Clinical Plan, Reports Second Quarter 2018 Financial Results and Revises Cash GuidanceManagement to Host Conference Call Today at 4:30 p.m. ET
NewLink Genetics Corporation announced its clinical plan and strategy, reported consolidated financial results for the second quarter of 2018, and revised its cash guidance.
NewLink Genetics Corporation announced that it will release its second quarter 2018 financial results on Tuesday, July 31, 2018.
Ebola cases, as well as cases of other significantly lethal viral outbreaks that have occurred has spurred researchers to focus on the development of antivirals that can treat the illnesses.
NewLink Genetics Announces Positive Updated Phase 1 Data with Indoximod Plus Radio-Immunotherapy for Pediatric Patients with DIPG Presented at ISPNO 2018
NewLink Genetics Corporation reported that updated Phase 1 data evaluating indoximod plus front-line radiation and maintenance chemotherapy were presented Sunday, July 1, at the ISPNO 2018 Annual Meeting.
NewLink Genetics Announces Updated Data for Indoximod Plus Radio-Immunotherapy in DIPG to be Presented at ISPNO 2018 Meeting
NewLink Genetics Corporation announced that updated data for patients with diffuse intrinsic pontine glioma (DIPG) from NLG2105, a Phase 1 study evaluating indoximod in combination with radiation and chemotherapy for the treatment of pediatric patients with progressive brain tumors, will be presented at the International Symposium on Pediatric Neuro-Oncology (ISPNO)
The Loncar Cancer Immunotherapy Index has reduced the number of immunotherapy-focused companies from 30 to 25 and also swapped out a number of stocks as part of an effort to strengthen the index’s liquidity profile and ensure the holdings hold equal weight.
NewLink Genetics Announces Final Results from Two Phase 2 Studies of Indoximod Presented at ASCO 2018
NewLink Genetics Corporation announced that data from two Phase 2 studies of indoximod, used in combination with other agents, were presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.
Genentech, has terminated its research program with Ames, Iowa-based NewLink Genetics.
4/25/2018Sometimes it feels like biotech’s successes and failures come in waves—even when it involves entirely unrelated clinical programs. This past month has had many in industry feeling like they’re underwater.
Public health officials and scientists have had concerns about how long Ebola vaccines’ protection lasts. A new study shows that one of those vaccines confers at least two years of protection.
The following is a roundup of presentations and findings from multiple companies participating in the 2018 American Association for Cancer Research (AACR) in Chicago.
NewLink Genetics Outlines 2018 Business Priorities to Support Phase III Pivotal Trial of Indoximod Plus PD-1 Inhibitors
In addition, the company updated clinical and financial guidance and provided preliminary unaudited financial information for year-end 2017.
The presentation entitled, “Radio-chemo-immunotherapy using the IDO-inhibitor indoximod for children with progressive brain tumors in the phase 1 setting” showed the combination of indoximod plus radiation was well-tolerated.
Dr. Kennedy’s previous role at NewLink Genetics was Vice President of Clinical and Medical Affairs.
Management will host a conference call today at 8:30 a.m. ET.
Indoximod is aimed at treating patients with Stage IIb-IV melanoma.